Cadila Healthcare on Wednesday reported a 74.32 per cent decline in net profit at Rs 107.2 crore for the second quarter ended September 30.
The company had posted a net profit of Rs 417.5 crore during the same period of previous fiscal.
The net profit during the quarter includes an impairment charge of Rs 268 crore towards Levorphanol intangibles on account of entry of a new competitor, Cadila Healthcare said in a regulatory filing.
Total revenue from operations during the quarter under review stood at Rs 3,393.5 crore as against Rs 2,991.6 crore in the year-ago period, it added.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app